Highlights Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Delayed Hong Kong S.E. Other stock markets 10:38:06 08/05/2024 am IST			5-day change	1st Jan Change
1.38 ^HKD	-1.43%		-1.43%	-5.48%

03/04	Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus	MT
03/04	Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42	03/04	CI
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03	CI
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting	11/03	CI
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne	24/01	CI
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis	02/01	CI
Ascletis Pharma Gets Nod to Trial Acne Drug	05/12	MT
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne	05/12	CI
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure	29/23/29	CI
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma	26/23/26	CI
Ascletis' H1 Attributable Loss Narrows as Revenue Jumps	22/23/22	MT
Ascletis Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22	CI
Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis	20/23/20	CI
Ascletis Pharma to Shrink Loss in H1	18/23/18	MT
Ascletis Pharma Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2023	18/23/18	CI
Ascletis Pharma Inc. commences an Equity Buyback Plan for 108,713,400 shares, representing 10% of its issued share capital, under the authorization approved on June 29, 2023.	30/23/30	CI
Ascletis Pharma to Buyback Shares	30/23/30	MT
Ascletis Pharma Inc.'s Equity Buyback announced on June 15, 2023 has expired.	29/23/29	CI
Ascletis Pharma Inc. commences an Equity Buyback Plan for 108,713,400 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2022.	15/23/15	CI
Ascletis Pharma Proposes Up to HK$200 Million Share Repurchase; Shares Climb 5%	23/23/23	MT
Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection	08/23/08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Highlights

Filters